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GlycoproteinB (gB) isoneof theessential components
for infection by herpes simplex virus-1 (HSV-1). Al-
though several cellular receptors that associate with
glycoprotein D (gD), such as herpes virus entrymedia-
tor (HVEM)andNectin-1, havebeen identified, specific
molecules thatmediateHSV-1 infectionbyassociating
with gB have not been elucidated. Here, we found that
paired immunoglobulin-like type 2 receptor (PILR)
a associateswith gB, andcells transducedwithPILRa
become susceptible to HSV-1 infection. Furthermore,
HSV-1 infection of human primary cells expressing
both HVEM and PILRa was blocked by either anti-
PILRa or anti-HVEM antibody. Our results demon-
strate that cellular receptors for both gB and gD are
required for HSV-1 infection and that PILRa plays an
important role in HSV-1 infection as a coreceptor that
associates with gB. These findings uncover a crucial
aspect of the mechanism underlying HSV-1 infection.
INTRODUCTION
Herpes simplex virus-1 (HSV-1) is the prototype of the diverse
a-herpesvirus family, which generally causes mucocutaneous
lesions but also is involved in lethal encephalitis. HSV-1 estab-
lishes latent infections in neurons of peripheral ganglia and
may reactivate to cause recurrent lesions (Whitley and Roizman,
2001). Entry of HSV-1 into cells depends upon interactions
between cell-surface receptors and viral proteins on the virion.
Among the surface glycoproteins of HSV-1, gB, gD, gH, and
gL are involved in the entry of HSV-1, and mutant viruses that
lack one of these four glycoproteins cannot infect cells (Spear,2004). gD interacts with herpesvirus entry mediator (HVEM),
Nectin-1, and specific sites on heparan sulfate generated by cer-
tain 3-O-sulfotransferases (Montgomery et al., 1996; Geraghty
et al., 1998; Warner et al., 1998; Shukla et al., 1999). Because
gD is an essential glycoprotein for HSV-1 to infect a cell, interac-
tions between gD and these cellular receptors play an important
role in HSV-1 entry into cells (Spear et al., 2000). Although gD
itself is probably not a membrane fusogen, binding of gD with
cellular receptors induces membrane fusion mediated by the
gH/gL heterodimer and gB (Krummenacher et al., 2005).
Both gB and gH have been reported to play an essential role in
membrane fusion during HSV-1 infection (Cai et al., 1988;
Forrester et al., 1992; Turner et al., 1998). Although neither gB
nor gH/gL has an obvious hydrophobic fusion peptide sequence,
recent analyses suggested that gB and gH possess putative
fusion peptides that may be involved in membrane fusion during
HSV-1 infection (Gianni et al., 2005; Heldwein et al., 2006). On the
other hand, gBhasbeensuggested to associatewith cell-surface
heparan sulfate (Herold et al., 1994); however, cells deficient in
heparan sulfate synthesis are still permissive to HSV-1 infection
(Banfield et al., 1995), and mutant HSV-1, from which the polyly-
sine sequence in gB that is responsible for heparan sulfate bind-
ing is deleted, is still infectious (Laquerre et al., 1998). More
recently, it has been reported that a soluble form of gB binds to
heparan sulfate-deficient cells and blocks HSV-1 infection of
some cell lines (Bender et al., 2005). These findings suggest
that molecules other than heparan sulfate mediate HSV-1 infec-
tion by associating with gB. It has been reported that gC also
binds to heparan sulfate and is involved in the binding of HSV-1
to the cell surface, although gC-deficient virus is still infectious
(Herold et al., 1991). Therefore, binding of gC to heparan sulfate
is not essential for viral entry, similar to the binding of gB to
heparan sulfate (Herold et al., 1994; Laquerre et al., 1998).
Immune cells express an abundance of cell-surface receptors
that regulate their activation. In some cases, highly relatedCell 132, 935–944, March 21, 2008 ª2008 Elsevier Inc. 935
receptors have evolved where one receptor in the family has
inhibitory functions, whereas another receptor in the family me-
diates activating functions. Paired immunoglobulin like-type 2
receptor (PILR) is one of these ‘‘paired’’ receptor families (Four-
nier et al., 2000; Mousseau et al., 2000; Shiratori et al., 2004). The
inhibitory PILRa has an immunoreceptor tyrosine-based inhibi-
tion motif (ITIM) in its cytoplasmic domain and delivers inhibitory
signals (Fournier et al., 2000). By contrast, the activating PILRb
associates with the immunoreceptor tyrosine-based activation
motif (ITAM)-bearing DAP12 adaptor molecule and delivers acti-
vating signals (Shiratori et al., 2004). Because most mammals
possess PILR genes, PILR likely plays an important role in the
regulation of immune cells (Wilson et al., 2006). Previously, we
have shown that the mouse inhibitory PILRa and activating
PILRb specifically recognize mouse CD99, and these receptors
are involved in the regulation of immune responses (Shiratori
et al., 2004).
Here, we found that HSV-1-infected cells express a ligand for
inhibitory PILRa and that gB of HSV-1 is a ligand for PILRa. Fur-
thermore, we determined that interactions between gB and
PILRamediate HSV-1 infection. Analyses using PILRa-transfec-
tants, HSV-1 mutants, and primary cells expressing both HVEM
and PILR indicated that cellular receptors for both gB and gD are
required for HSV-1 infection.
RESULTS
Cloning of a PILRa Ligand Expressed
on HSV-1-Infected Cells
When we analyzed HSV-1-infected cells for ligands that bind
human PILRa, we found that HSV-1-infected human 293T
Figure 1. PILRa Ligand Expressed on
HSV-1-Infected Cells Is gB
(A) Expression of a ligand for PILRa on HSV-1-in-
fected cells. 293T cells or HSV-1 (strain F, VR3,
SC16, or KOS)-infected 293T cells were stained
with human PILRa-Ig (solid line) or a control Ig
fusion protein (CD200-Ig, dotted line).
(B) Immunoprecipitation of PILRa ligand from
HSV-1-infected cells. Lysates of HSV-1-infected
or noninfected 293T cells were immunoprecipi-
tated with PILRa-Ig, and immunoprecipitates
were separated by SDS-PAGE, followed by silver
staining.
(C) Western blot analysis of the HSV-1 PILRa
ligand. Lysate from HSV-1-infected cells was
immunoprecipitated with PILRa-Ig, Nectin-1-Ig,
or CD200-Ig (control). Immunoprecipitates were
separated by SDS-PAGE and were blotted with
anti-gB or anti-gD Ab. Ig fusion proteins used for
immunoprecipitation were detected by anti-
human IgG Ab.
cells were specifically stained with hu-
man PILRa-Ig fusion protein (Figure 1A).
PILRa-Ig bound equally to cells infected
with several HSV-1 strains. Similarly,
NIH 3T3 cells or Vero cells infected with
HSV-1 were also recognized by human PILRa-Ig fusion protein
(data not shown). This suggested that HSV-1 encodes a ligand
for PILRa or that HSV-1 induces a cellular ligand for PILRa in
infected cells. In order to identify the ligand for human PILRa
present on HSV-1-infected cells, infected cells were lysed and
the ligand for PILRa was immunoprecipitated with PILRa-Ig,
followed by SDS-PAGE analysis. PILRa-Ig, but not control Ig,
specifically precipitated 110 kDa molecules from HSV-1-in-
fected cells (Figure 1B). We extracted the 110 kDa protein and
then analyzed the protein by using LC/MS/MS mass spectrom-
etry. Surprisingly, 29 peptide sequences that were identical to
gB were obtained by the analysis (Figure S1). In addition, 2 pep-
tide sequences that were identical to gH were also identified.
This suggested that the ligand detected on HSV-1-infected cells
is likely to be gB and not a cellular ligand induced by HSV-1
infection.
Specific Binding of PILRa to gB
In order to confirm that the ligand for PILRa is gB, lysates of HSV-
1-infected cells were immunoprecipitated with PILRa-Ig, fol-
lowed by western blot analysis. The 110 kDa protein precipitated
from HSV-1-infected cells by PILRa-Ig was confirmed to react
with an anti-gB mAb but not anti-gD mAb (Figure 1C). On the
other hand, Nectin1-Ig clearly precipitated gD, as well as small
amounts of gB. Control Ig did not precipitate either gB or gD.
This indicated that the 110 kDa protein precipitated by PILRa-Ig
is mainly gB.
Next, we analyzed the specificity of binding of PILRa to gB.
293T cells transfected with a full-length gB cDNAdid not express
significant amounts of gB on the cell surface (data not shown).
Therefore, we generated a mutant gB that lacks the C-terminal936 Cell 132, 935–944, March 21, 2008 ª2008 Elsevier Inc.
40 amino acids in the cytoplasmic tail (gBDC), because the cyto-
plasmic domain of gB contains an intracellular retention signal
that impairs cell-surface expression of wild-type gB (Beitia Ortiz
de Zarate et al., 2004). Unlike wild-type gB, gBDC was ex-
pressed well on the cell surface of 293T cells upon transient
transfection. We cotransfected gBDC, gD, or gH and gL together
with GFP into 293T cells and analyzed binding of PILRa-Ig and
Nectin-1-Ig to GFP-positive transfectants by flow cytometry
(Figure 2A). Cell-surface expression of these glycoproteins was
confirmed by staining with mAbs against these glycoproteins.
PILRa-Ig clearly bound cells transfected with gBDC but not gD
or gH and gL. Mouse PILRa-Ig also recognized cells transfected
with gBDC, but not with gD or gH and gL (data not shown). On the
other hand, Nectin-1-Ig fusion protein bound cells expressing
gD, but not gB or gH and gL. These data indicated that PILRa
specifically binds to gB, but not gD or gH and gL.
To further confirm the specificity of the binding of PILRa to gB,
we analyzed cells infected with gB-deficient HSV-1. Because
gB-deficient virus does not infect cells, gB-deficient virus that
possesses gB protein on the virion was produced by using
gB-transfected complementing cells (Cai et al., 1988). Similar
to the data presented in Figure 1, cells infected with wild-type
HSV-1 were stained with anti-gB and anti-gD mAb, as well as
PILRa-Ig (Figure 2B). Cells infected with gB-deficient HSV-1
were stained with anti-gD mAb, but not with anti-gB mAb or
PILRa-Ig fusion protein. Cells infected with a revertant virus
that expresses wild-type gB were recognized by both anti-gB
Figure 2. Specific Interaction between
PILRa and gB
(A) Specific binding of human PILRa to gB. Mutant
gB that lacks the C terminus 40 amino acids, gD,
or gH and gL was cotransfected with GFP into
293T cells. Transfected cells were stained with
PILRa-Ig and Nectin-1-Ig fusion proteins, and
anti-gB, anti-gD, and anti-gH mAbs (solid line).
Cells were also stained with control Ig fusion
protein or control mAb (dotted line). The staining
patterns of GFP-positive cells are shown.
(B) PILRa-Ig does not recognize cells infected with
gB-deficient HSV-1. Noninfected 293T cells and
293T cells infected with wild-type HSV-1, gB-defi-
cient HSV-1, or revertant HSV-1 were stained with
PILR-Ig, Nectin-1-Ig, anti-gB mAb, and anti-gD
mAb (solid line). Cells were also stained with con-
trol Ig fusion protein or control mAb (dotted line).
mAb and PILRa-Ig fusion protein. These
data indicated that PILRa specifically
recognizes gB and suggest that the small
amounts of gH detected by mass spec-
trometry analysis were likely a result of
coprecipitation with gB.
HSV-1 Infection of PILR
Transfectants
gB is a viral protein conserved in all her-
pesviruses and plays an important role
in HSV-1 infection (Cai et al., 1988; Held-
wein et al., 2006). HSV-1 that lacks gB cannot infect cells (Cai
et al., 1988). Although receptors for gB have been suggested
to be expressed on the cell surface (Bender et al., 2005), specific
receptors that associate with gB and mediate HSV-1 infection
have not been identified. We analyzed whether the interaction
between gB and PILRa is involved in HSV-1 infection. Because
CHO-K1 cells express an unknown endogenous cellular ligand
for PILRa, we isolated PILRa-ligand-negative CHO-K1 cells by
flow cytometry and transfected human PILRa into these
PILRa-ligand-negative CHO-K1 cells in order to avoid potential
interactions between human PILRa and the endogenous ham-
ster PILRa ligand. When the PILRa-ligand-negative CHO-K1
cells were transfected with human PILRa, these cells were effec-
tively infected by HSV-1 expressing a GFP marker, whereas
mock-transfected CHO-K1 cells were not infected by GFP-
HSV-1 (Figures 3A and 3B). Similar results were obtained when
HSV-1 infection was analyzed by fluorescence microscopy
(Figure 3C). These data indicated that human PILRa is involved
in HSV-1 infection by associating with gB.
Generation of Neutralizing Anti-Human
PILRaMonoclonal Antibody
We addressed whether a direct interaction between human
PILRa and gB is involved in HSV-1 infection. For this purpose,
we generated a mAb that specifically blocks the interaction
between human PILRa and gB. We identified an anti-PILRa
mAb (M4) that completely blocked the binding of PILRa-Ig toCell 132, 935–944, March 21, 2008 ª2008 Elsevier Inc. 937
gB-transfected cells. As shown in Figure S2A, anti-PILRa mAb
M4 specifically recognized mouse Ba/F3 cells transfected with
human PILRa but not parental Ba/F3 cells. Anti-PILRa mAb M4
did not bind to HVEM- or Nectin-expressing cells (data not
shown). Furthermore, when human PILRa-Ig fusion protein was
preincubated with the anti-PILRa M4 mAb, the PILRa-Ig fusion
protein did not bind the cells transfected with the gBDC
(Figure S2B). This indicated that the anti-PILRa M4 mAb com-
pletely blocks the interaction between human PILRa and gB.
Inhibition of HSV-1 Infection of PILRa Transfectants
by Anti-PILRa mAb or Soluble PILR
We analyzed whether the anti-PILRa mAb blocks HSV-1 infec-
tion of PILRa-transfected cells. When human PILRa transfec-
tants were infected with HSV-1 in the presence of anti-PILRa
mAb, infection was completely blocked by the anti-human PILRa
mAb in a dose-dependent manner (Figure 4A). By contrast, an
isotype-matched mAb did not affect HSV-1 infection of PILRa
transfectants. In addition, other anti-PILRa mAbs that did not
block the binding of PILRa to gB also did not block HSV-1 infec-
tion of PILRa transfectants (data not shown).
Because PILRa-Ig directly binds to gB of HSV-1, soluble
PILRa-Ig fusion protein might block the interaction between gB
and human PILRa. To test this possibility, we analyzed HSV-1 in-
fection of PILRa-expressing cells in the presence or absence of
the human PILRa-Ig fusion protein. As shown in Figure 4B, HSV-
1 infection of human PILRa-transfected CHO-K1 cells was sig-
nificantly blocked by PILRa-Ig fusion protein, but not by a control
Ig fusion protein. These data indicated that a direct interaction
between PILRa and gB mediates HSV-1 infection.
Role of gD in Infection of PILRa-Expressing Cells
gD, as well as gB, is an essential viral protein for HSV-1 infection
because gD-deficient HSV-1 is noninfectious (Ligas and John-
son, 1988). We addressed whether gD is involved in PILRa-
mediated HSV-1 infection. PILRa-transfected CHO cells were
Figure 3. HSV-1 Infection of PILRa-Transfected CHO-K1
Cells
(A) PILRa-ligand-negative CHO-K1 cells were transiently trans-
fected with the pMx-IRES-DsRed expression vector containing
human PILRa. Transfected CHO-K1 cells were infected with
HSV-1-GFP, and cells expressing GFP within the DsRed-positive
population were analyzed by flow cytometry.
(B) Proportions of cells expressing GFP, gated on human PILRa
(DsRed)-positive cells, are shown. Mean ± SD of triplicate analy-
ses are shown.
(C) CHO-K1 cells were transiently transfected with PILRa-IRES-
DsRed or mock-IRES-DsRed expression vectors, and cells
expressing DsRed were purified by using a cell sorter. The
transfected cells were infected with HSV-1-GFP, and expression
of GFP was analyzed by fluorescence microscopy.
infected with a gD-deficient virus produced by normal
Vero cells (gD ()-HSV) or gD-expressing comple-
menting Vero cells (gD (+)-HSV). gD itself has been
reported to be dispensable for the production of
HSV-1 virions (Ligas and Johnson, 1988). Indeed,
equal amounts of gB were detected in these viruses
by western blot analysis, suggesting that the amounts of virions
were similar (Figure S3). When PILRa-transfected CHO cells
were inoculated with these gD-deficient HSV-1, gD (+)-HSV
was able to infect the PILRa-transfected CHO cells but not gD
()-HSV, at least not to any significant extent (Figure 5A). This in-
dicated that gD is required for PILRa-mediated HSV-1-infection.
We then addressed whether binding of gD to certain cellular re-
ceptors are required for HSV-1 infection of PILRa-transfected
CHO cells. We generated a gD-Ig fusion protein and tested the
ability of this fusion protein to block HSV-1 infection of PILRa-
transfected CHO. As shown in Figure 5B, HSV-1 infection of
PILRa-transfected CHO cells was inhibited by the gD-Ig fusion
protein in a dose-dependent manner (Figure 5B). These data
suggested that association of gD with certain cell surface mole-
cules is required for PILRa-mediated HSV1 infection.
In order to further examine the mechanism of PILRa-mediated
HSV-1 infection, we employed a cell-fusion assay. gB, gD, gH,
and gL were cotransfected with GFP into CHO cells, and PILRa
was cotransfected with RFP into CHO cells. Purified GFP- or
RFP-positive cells were cocultured for 8 hr, and cell fusion was
analyzed by fluorescencemicroscopy. When CHO cells cotrans-
fectedwith gB, gD, gH, andgLwere coculturedwithPILRa-trans-
fected CHO cells, significant numbers of CHO cells expressing
both GFP and RFP were observed (Figure 6). Furthermore, cells
expressing both GFP and RFP were multinucleated. CHO cells
cotransfected with gB, gD, gH, and gL did not show cell fusion
with mock-transfected CHO cells. CHO cells transfected with
gD, gH, and gL also did not show cell fusion with PILRa-trans-
fected CHO cells. When CHO cells transfected with gB, gH,
and gL were analyzed, most cells did not show cell fusion with
PILRa-transfected CHO cells. However, a very low frequency of
CHO cells transfected with gB, gH, and gL, but not gD, showed
cell fusion with PILRa-transfected CHO cells (Figures 6 and S4).
The size of fused CHO cells transfected with gB, gH, and gL
were significantly smaller compared to CHO cells transfected
withgB, gD, gH, andgL. Thus, theefficiencyof cell fusion induced938 Cell 132, 935–944, March 21, 2008 ª2008 Elsevier Inc.
Figure 4. Inhibition of HSV-1 Infection by Anti-PILRamAb
or by PILRa-Ig
(A) Inhibition of HSV-1 infection by anti-PILRamAb. CHO-K1 cells
were transiently transfected with human PILRa in the pMx-IRES-
DsRed expression vector, and cells were infected with HSV-1-
GFP in the presence of various concentrations of anti-PILRa or
control mAb. Proportions of infected cells were determined by
flow cytometry.
(B) Inhibition of HSV-1 infection by PILRa-Ig fusion protein. CHO-
K1 cells transiently transfected with human PILRa were infected
with HSV-1-GFP in the presence of various concentrations of
PILRa-Ig or control Ig fusion protein. The proportion of infected
cells was determined by flow cytometry. Mean ± SD of triplicate
analyses are shown.by CHO cells transfected with only gB, gH, and gL was much
lower than that by CHO cells transfected with gB, gD, gH, and
gL, just as viral entry in the absence of gD was also very much
reduced in efficiency (Figure 5A).
These data indicated that interactions between gB and PILRa
are involved in membrane fusion during HSV-1 infection. gD-de-
ficient virus infected PILRa-transfected cells very inefficiently, if
at all, and minimal cell fusion was observed by interactions be-
tween gB and PILRa in the absence of gD. Therefore, interaction
of gDwith certain cellular molecules is required for optimal mem-
brane fusion even in the presence of gB and PILRa.
PILRa-Mediated HSV-1 Infection of Primary Cells
We addressed whether PILRa is involved in the infection of
primary human cells. Previously, PILRa has been reported to
be expressed mainly on monocytes, granulocytes, and dendritic
cells (Fournier et al., 2000). When amounts of PILRa transcript in
various human tissues were analyzed by quantative real-time
RT-PCR, significant amounts of PILRa transcripts were detectednot only in PBMC but also in various tissues including the ner-
vous system (Figure S5A). In particular, brain and cerebellum ex-
pressed relatively high amounts of PILRa transcripts. Nucleic
acid sequences of PCR products amplified from whole brain
and cerebellum were identical to PILRa, and similar results
were obtained by using different primer sets (data not shown).
When tissue sections from several tissues were analyzed by
immunohistochemistry, various types of cells including neurons
were stained with anti-PILRamAb (Figure S5B). These data sug-
gested that PILRa is broadly expressed in various tissues, and
expression of PILRa is not limited to the myeloid lineage.
When expression of PILRa, HVEM, and Nectin-1 on human
PBMC was analyzed by flow cytometry, all of the CD14-positive
monocyte population expressed both HVEM and PILRa, but not
Nectin-1 (Figure 7A). On the other hand, a CD14-negative po-
pulation, which predominantly consisted of lymphocytes, ex-
pressed HVEM, but not significant amounts of PILRa or Nectin-
1. Expression levels of HVEMon theCD14-negative and -positive
populations were similar. Therefore, we separated PBMC intoFigure 5. Requirement of gD in PILRa-Mediated HSV-1
Infection
(A) Requirement of gD in HSV-1 infection of PILRa-expressing
cells. PILRa- or mock-transfected CHO cells were infected with
gD-deficient virus produced by normal Vero cells (gD() HSV-1,
closed circle) or gD-transfected Vero cells (gD(+) HSV-1, open
circle). Proportions of ICP4 (a viral protein produced immediately
after infection) -positive cells, detected by flow cytometry, are
shown as mean ± SD of triplicate analyses.
(B) Inhibition of HSV1 infection by soluble gD. PILRa- or mock-
transfected CHO cells were infected with HSV-GFP in the pres-
ence of gD-Ig (closed circle) or control Ig (open circle) fusion
protein. Proportions of GFP-positive cells are shown as mean ±
SD of triplicate analyses.Cell 132, 935–944, March 21, 2008 ª2008 Elsevier Inc. 939
CD14-positive and -negative populations and infected these
cells with HSV-1 in the presence or absence of a neutralizing
anti-PILRamAb (Figure 7B).
CD14-positive monocytes, which express both PILRa and
HVEM, were susceptible to HSV-1 infection. In contrast, HSV-1
did not infect the CD14-negative population, although the
CD14-negative population expresses HVEM at the same level
as the CD14-positive monocytes. gD-Ig fusion protein bound
CD14-negative population (Figure S6A), and binding of gD-Ig fu-
sion protein to CD14-negative population was blocked by anti-
HVEM Ab (Figure S6B). This suggested that HVEM expressed
on the CD14-negative population is accessible to gD, although
the CD14-negative population was resistant to HSV-1 infection.
Furthermore, HSV-1 infection of monocytes, which express both
PILRa and HVEM, was efficiently blocked by anti-human PILRa
mAb, but not by a control mAb (Figure 7B). In addition, HSV-1 in-
fection of monocytes was also efficiently blocked by antiserum
against HVEM but not by control serum (Figure 7C). Similar to
PILRa-transfected CHO cells, the gD-deficient virus did not in-
fect monocytes (Figure 7D). These data demonstrated that inter-
actions of both gB and gD with their specific cellular receptors
are required for HSV-1 infection of primary cells and that PILR
functions as a coreceptor for HSV-1 infection. This also indicated
that cellular receptors for either gB or gD alone are not enough to
Figure 6. Cell FusionMediated by Interaction between gB and PILRa
Cell fusion assay between CHO cells transfected with HSV-1 glycoproteins
and PILRa. gB, gD, gH, and gL (BDHL), gB, gH, and gL (BHL), or gD, gH,
and gL (DHL) were cotransfected into CHO-K1 cells with GFP. PILRa or control
plasmid (Mock) was cotransfected into CHO-K1 cells with RFP. GFP- and
RFP-expressing cells were purified by using flow cytometry and were cocul-
tured. After 8 hr, cells were analyzed by fluorescence microscopy. Photo-
graphs taken by green and red filters were overlaid (Overlay). Green and red
colors of nonfused cells were converted to gray color, and yellow colors of
fused cells were left unchanged (Processed color). Photographs taken using
phase contrast are also shown (Phase). Multinuclear cells are circled in red.940 Cell 132, 935–944, March 21, 2008 ª2008 Elsevier Inc.mediate HSV-1 infection. Resistance of CD14-negative PBMC
that express HVEM, but not PILRa, to HSV-1 infection also
suggests that cellular receptors for gD alone are not sufficient
to mediate HSV-1 infection.
DISCUSSION
Here, we have shown that PILRa mediates HSV-1 infection by
associating with gB. We have also demonstrated that anti-PILRa
or anti-HVEM Ab blocks HSV-1 infection of monocytes, which
constitutively express both PILRa and HVEM. Furthermore, we
have found that cellular receptors for gD are required for HSV-
1 infection of PILRa-expressing cells by use of gD-deficient
HSV-1 and anti-HVEM serum. These data indicated that interac-
tions of both gB and gD with specific cellular receptors are re-
quired for HSV-1 infection. These findings also established that
Figure 7. PILRa-Mediated HSV-1 Infection in Primary Cells
(A) Expression of HVEM, Nectin-1, and PILRa on human PBMC. PBMC were
stained with anti-HVEM, anti-Nectin-1, or anti-PILRa mAbs, along with anti-
CD14 mAb.
(B) PILRa-mediated HSV-1 infection of CD14-positive PBMC. Freshly isolated
human CD14-positive or -negative PBMC were infected with various amounts
of HSV-1-GFP in the presence or absence of anti-human PILRamAb or control
mAb (10 mg/ml), and the proportion of infected cells was determined by flow
cytometry.
(C) Role of HVEM in HSV-1 infection of monocytes. Freshly isolated human
CD14-positive monocytes were infected with HSV-1 GFP in the presence of
anti-HVEM serum or control serum at the indicated concentrations.
(D) Role of gD in HSV-1 infection of primary monocytes. Freshly isolated
human CD14-positive monocytes were infected with gD-deficient virus
produced by normal Vero cells (gD[] HSV-1) or gD-transfected Vero cells
(gD[+] HSV-1). Proportions of ICP4-positive (infected) cells were determined
by flow cytometry. All the data are shown as mean ± SD of triplicate analyses.
cellular receptors for either gB or gD alone are not enough tome-
diate HSV-1 infection. Resistance of CD14-negative PBMC that
express HVEM, but not PILRa, to HSV-1 infection also revealed
that cellular receptors for gD alone are not sufficient to mediate
HSV-1 infection of primary cells. Taken together, PILRa func-
tions as an entry coreceptor for HSV-1 infection.
CHO cells transfected with cellular receptors for gD, such
as HVEM or Nectin-1, become susceptible to HSV-1 infection
(Montgomery et al., 1996; Geraghty et al., 1998; Warner et al.,
1998; Shukla et al., 1999). CHO cells transfected with PILRa
also become susceptible to HSV-1 infection. Interestingly, solu-
ble gD blocked the HSV-1 infection of PILRa-transfected CHO.
In addition, gD-deficient HSV-1 did not infect PILRa-transfected
CHO cells. These data indicated that association of gB with
PILRa alone does not mediate HSV-1 infection. CHO cells might
express certain receptors for gD that alone are not enough tome-
diate HSV-1 infection. Indeed, CHO cells can be infected, albeit
very inefficiently, by some strains ofHSV, indicating the presence
of weak entry receptor activity (Shieh et al., 1992). Significant
amounts of transcripts for D-glucosaminyl 3-O-sulfotransfer-
ase-3, which generates the specifically modified heparan sulfate
recognized by gD (Shukla et al., 1999), were detected in CHO
cells by RT-PCR (data not shown). Therefore, low levels of gD
ligands expressed on CHO cells, which do not mediate HSV-1
infection by themselves, seem to be required for HSV-1 infection
even when a specific cellular receptor for gB, PILRa, is ex-
pressed. Furthermore, it has recently been reported that soluble
gB blocks HSV-1 infection of several cell lines (Bender et al.,
2005). Their findings also support the important role of cellular
receptors for both gB and gD in HSV-1 infection. On the other
hand, gB, as well as gC, binds cell surface heparan sulfate (Her-
old et al., 1991, 1994). However, the interaction of these envelop
glycoproteins with heparan sulfate is involved in the binding of
virus to the cell surface but not in viral entry (Herold et al., 1991;
Laquerre et al., 1998). Therefore, PILRa plays an important role
in HSV-1 infection as a cellular entry receptor for gB in collabora-
tion with cellular receptors for gD.
The association of gDwith a cellular receptor is thought to trig-
ger membrane fusion mediated by other viral envelope proteins,
gH/gL and gB (Krummenacher et al., 2005). gB has been
proposed as a viral fusion protein, together with the gH/gL heter-
odimer (Turner et al., 1998). Recently, it has been reported that
gD and gH/gL are sufficient for hemi-fusion of membranes but
that gB is required to form a fusion pore (Subramanian and
Geraghty, 2007). Indeed, gH possesses a putative fusion se-
quence, and mutations in this sequence cause loss of infectivity
(Gianni et al., 2005). Recent analysis of the crystal structure of gB
suggested that gB exhibits a structure similar to that of vesicular
stomatitis virus (VSV) G protein (Heldwein et al., 2006; Roche
et al., 2006), which is fully competent by itself to mediate viral en-
try and viral fusion. The regions of gB homologous to the VSV G
fusion loops are considered to be putative gB fusion loops even
though their hydrophobicity is not representative for general
fusion peptides (Heldwein et al., 2006). Considering that cellular
receptors for both gB and gD are required for HSV-1 infection,
interaction between gB and PILRa might function, along with
gD-receptor interactions, to trigger putative gB fusion loops to
contact cell membranes at viral fusion.PILRa possesses an ITIM in its cytoplasmic domain, and
crosslinking of PILRa with Ab downregulated the activation of
PILRa-expressing cells (Fournier et al., 2000). Therefore, PILRa
might be involved in immune evasion by associating with gB.
On the other hand, the ITIM sequence shares a motif with the
tyrosine-based sorting signals that are involved in the internaliza-
tion of cell-surface molecules (Ohno et al., 1995). However,
mutant PILRa that lacks the cytoplasmic domain still mediates
HSV-1 infection (data not shown). Therefore, the ITIM sequence
of PILRa is not required for HSV-1 entry.
When we analyzed PILRa expression in various tissues, we
found that the expression of PILRa is not restricted to the mye-
loid linage. Significant amounts of PILRa were detected in vari-
ous tissues, including the nervous system. This suggested that
PILRa might be involved in HSV-1 infection in various tissues.
However, because expression levels of PILRa in most of these
tissues are low compared to that in PBMC, there might be other
receptors that mediate HSV-1 infection by associating with gB.
In the present study, we have identified for the first time a specific
cell-surface receptor that mediates HSV-1 infection by associat-
ing with gB. Cellular receptors for both gB and gD have been
shown to play an important role in HSV-1 infection of human
primary cells and other cells. Thus, it seems likely that an under-
standing of HSV-1 entry and membrane fusion will require defin-
ing the sequence and consequences of the binding of gD and gB
to two different sets of entry receptors.
EXPERIMENTAL PROCEDURES
Cell Lines
293T and COS-7 were purchased from Riken Cell Bank, Japan. CHO-K1 was
purchased from Health Science Research Resources Bank, Japan. CHO-K1
cells were stained with PILRa-Ig, and cells that did not stain with PILR-Ig
were isolated by flow cytometry using a FACSAria (Becton Dickinson). A single
cell clone obtained from the sorted cells was used as the PILR-ligand-negative
CHO-K1 cell line for introduction of human PILRa.
Plasmids
A cDNA fragment of human PILRa (GenBank accession number: AF161080)
was amplified by RT-PCR from human PBMC cDNA and cloned into pMXs-
IRES-DsRed vector.MouseMHCclass I H2-Kb cloned into pMXs-IRES-DsRed
wasused for control transfections. cDNA fragmentscorresponding to theextra-
cellular domain of human PILRa, HVEM, and Nectin-1 were amplified by PCR,
and these fragments were inserted into the Xho I cloning site of a modified
pME18S expression vector that contained a mouse CD150 leader segment at
the N terminus and the Fc segment of human IgG1 at the C terminus (GenBank
accessionnumber:AAH14667;positions: 249–479), inwhich the leucinesat po-
sition 266 and 267 of the Fc were mutated to alanine and glutamine, respec-
tively, in order to reduce the affinity of binding to cellular Fc receptors (Shiratori
et al., 2004). Furthermore, histidine at position 467 was mutated to arginine in
order to reduce the affinity of binding to HSV-1 Fc receptor (glycoprotein E)
(Chapman et al., 1999). cDNA fragments corresponding to the HSV-1 gB that
lacks cytoplasmic 40 amino acids (GenBank accession number: M14164),
full-length gD (GenBank accession number: X14112), gH, and gL were ampli-
fied by PCR and were cloned into pcDNA3.1 expression vector (Invitrogen).
Primersused for PCRaredescribed inSupplemental ExperimentalProcedures.
gB-Expressing Cell Line
Because gB-deficient virus is noninfectious, we generated gB transfectants to
produce infective gB-deficient virus. A 3.3 kb Xho I-BamHI fragment of the
cosmid pBC1014 (Kawaguchi et al., 1997), encoding the entire gB open-read-
ing frame and its flanking sequences, was cloned into pBluescript KS+Cell 132, 935–944, March 21, 2008 ª2008 Elsevier Inc. 941
(Stratagene) to yield pBS-gBL. pBC1014 was kindly provided by Dr. Bernard
Roizman. A DNA fragment encoding HSV-1(F) nucleotides 55,667–55,803 am-
plified by PCRwas digested with Xho I and Not I and substitutedwith the Xho I-
Not I fragment of pBS-gBL. The resultant plasmid pBS-gB contains HSV-1(F)
nucleotides 55,80352,589. A DNA fragment containing the promoter region
of a27 gene (HSV-1[F] nucleotides 112,701–113,673) amplified by PCR and
a Xho I-KpnI fragment of pBS-gB, containing the entire open-reading frame
of gB and its polyadenylation signal, were sequentially cloned into pBluescript
KS+ to yield pa27-gB. To construct pcDNA5/FRT/a27-gB, the Sph I-KpnI frag-
ment of pa27-gB was cloned into the Sph I and KpnI sites of pcDNA5/FRT
(Invitrogen). Flp-In-CV-1/a27-gB cells, which express gB proteins under con-
trol of the a27 promoter, were generated by cotransfection of pcDNA5/FRT/
a27-gB with pOG44 (Invitrogen) into Flp-In-CV-1 (Invitrogen) according to
the manufacturer’s instructions.
Viruses
Wild-type HSV-1 (F, VR3, SC16, and KOS strains) and recombinant HSV-1
(strain F) carrying GFP (YK333) (Tanaka et al., 2004) were used in this study.
The recombinant HSV-1 expresses GFP driven by the Egr-1 promoter; the
virus particle itself does not contain GFP. Therefore, only the cells infected
with HSV-1 express GFP. Indeed, GFP expression in HSV-1-GFP infected
cells was well correlated with ICP0 expression (Tanaka et al., 2004), indicating
that cells expressing GFP were infected with HSV-1. Virus titers were deter-
mined by using Vero cells as previously described (Tanaka et al., 2004). gD-de-
ficient virus (Warner et al., 1998) and gD-transfected Vero cells (VD60) (Ligas
and Johnson, 1988) were previously described. gD-deficient virus produced
in gD-transfected Vero cells and wild-type virus produced in normal Vero cells
were used to infect normal Vero cells and viruses were collected 2 days later.
Because gD-deficient virus does not infect cells, the amount of virions was
determined by western blot analysis of gB. The viral stocks containing the
same amount of gB were sequentially diluted and used for infection of
PILRa-expressing cells.
gB-deficient virus HSV-1 was constructed basically as described previously
(Tanaka et al., 2004). A mutated HSV-1 genome carrying the substitution of
a part of the gB sequence (HSV-1[F] nucleotides 53,617–55,793), which en-
codes the signal peptides and the endoplasmic region of gB, with the kana-
mycin-resistance gene was generated in E. coli YEbac202 harboring the
full-length HSV-1 genome cloned into a bacmid and pGETrec (Narayanan
et al., 1999), as described previously (Tanaka et al., 2005). The gB deletion vi-
rus (YK701) was reconstituted by transfection of the mutated HSV-1 genome
into Flp-In-CV-1/a27-gB, as described previously (Tanaka et al., 2003). Dele-
tion of the gB sequence was confirmed by Southern blotting.
Revertant virus that carries gB was constructed from the gB-deficient bac-
mid. A DNA fragment containing HSV-1(F) nucleotides 55,793–56,586 ampli-
fied by PCR, and the Xho I - BamHI fragment of pBC-gBL was sequentially
cloned into pCR2.1 (Invitrogen) to yield pCRxgB. pCRxgB contains HSV-1(F)
nucleotides 56,58652,589. In recombinant virus YK702, the gB sequence de-
leted from YK701 was restored by cotransfection of YK701 DNA with pCRxgB
into Flp-In-CV-1/a27-gB cells. Plaques were isolated and purified on Vero
cells. Restoration of the original sequencewas confirmed by Southern blotting.
Ig Fusion Protein
Plasmids for Ig fusions proteins with a mutant Fc portion that has low affinity to
cellular Fc receptor and HSV-1 Fc receptor (glycoprotein E) were constructed
as described above. COS-7 cells were transiently transfected with pME18S-
human PILRa-IgG Fc, pME18S-human HVEM-IgG Fc, pME18S-human Nec-
tin-1-IgG Fc, or pME18S-gD-IgG Fc vector, and culture supernatants were
collected. As a control, purified human CD200-Ig Fc fusion protein was used
(Shiratori et al., 2005). Ig fusion proteins were purified by protein A affinity
chromatography.
Establishment of Monoclonal Antibodies
BALB/c mice were immunized with human PILRa-Ig fusion protein and Titer-
Max Gold adjuvant. Two weeks after immunization, lymph node cells were
fused with SP2/0, and hybridomas that recognized human PILRa-transfected
Ba/F3 cells (mouse pro-B cell line) were obtained. Among the hybridomas that
recognize human PILRa, specificmAbs that blocked the binding of PILRa-Ig to942 Cell 132, 935–944, March 21, 2008 ª2008 Elsevier Inc.cells expressing the extracellular domain of gBwere selected. One hybridoma,
M4 (IgG1 isotype), which blocked the binding of PILRa-Ig to the extracellular
domain of gB, was used in this study. Antibody produced in culture superna-
tant was purified by protein A affinity chromatography. As a control, anti-Flag
mAb M2 (mouse IgG1, Sigma) was used. Anti-HVEM mAb (clone 122)
and anti-Nectin-1 mAb (clone CK8) were purchased from MBL and Zymed,
respectively.
Transfection and Infection
CHO-K1 cells were transiently transfected with Lipofectamine 2000 (Invitro-
gen) or GeneJuice (Novagen) in F-12 medium containing 10% FCS. The day
after transfection, the medium was replaced with F-12 containing 1% FCS.
Two days after transfection, transfectants were mixed with HSV-1-GFP, fol-
lowed by centrifuge at 32C at 11003 g for 2 hr. PBMCwere obtained by using
Ficoll-Paque PLUS (Amersham Biosciences) and CD14-positive and -negative
cells were separated by using a MACS purification system (Miltenyi Biotec).
PBMC were cultured for 2 hr in Advanced RPMI-1640 (Invitrogen) containing
1% FCS and were mixed with HSV1-GFP, followed by centrifuge at 32C at
1100 3 g for 2 hr. Twelve hours after infection, cells were fixed with 4% para-
formaldehyde dissolved in phosphate buffered saline, and expression of GFP
or DsRed was analyzed by using a FACSCalibur (Becton Dickinson). In the ex-
periments in which HSV-1 that has no fluorescence marker was used, HSV-1-
infected cells were fixed with paraformaldehyde and were permeabilized by
Triton-X and stained with anti-ICP4 mAb (clone 10F1, Virusys Corporation),
and the proportions of stained cells were determined by flow cytometry. In
the blocking experiments, cells were infected with HSV-1 in the presence of
control or anti-HVEM serum (Montgomery et al., 1996).
Flow Cytometry
Cells were incubated with human Ig fusion proteins or primary mouse mAbs,
followed by PE-conjugated anti-human IgG or anti-mouse IgG Ab (Jackson
Immunoresearch). Expression of viral glycoproteins was analyzed by using
anti-gB (clone 1105, Rumbauhg-Goodwin Institute), anti-gD (clone DL6), and
anti-gH (clone 53-S, ATCC) mAbs. Stained cells were analyzed by using
a FACSCalibur. Data were analyzed by CellQuest Pro software (Becton
Dickinson) or FlowJo software (Tree Star, Incorporated).
Immunoprecipitation and Immunoblotting
Cells were disrupted in lysis buffer (20 mMTris, 150mMNaCl, pH 7.5) contain-
ing 1% Brij 98 (Sigma). Lysates were immunoprecipitated with PILRa-Ig or
Nectin-1-Ig. The immunoprecipitates were eluted by boiling with SDS-PAGE
sample buffer and separated on 5%–20% polyacrylamide gels. Gels were
silver stained (Bio-Rad) or proteins were transferred onto PVDF membranes
(Millipore). The membranes were blotted with anti-gB mAb (clone 1105),
anti-gD (clone DL6) mAb, or rabbit anti-HSV Ab (ab20535, Abcam).
In-Gel Digestion and Mass Spectrometry Analysis
Gel pieces from SDS-PAGE were washed and treated with destaining solution
(15mMpotassium ferricyanide, 50mMsodium thiosulfate). After reductionwith
10 mM DTT, proteins were alkylated with 55 mM iodoacetamide and then di-
gested for 16 hr at 37Cwith sequence-grade trypsin (Promega). The resulting
peptides were extracted from the gel with 0.1% TFA in 2% ACN. The extracts
were evaporated, and the residue was dissolved with 0.1% TFA in 2% ACN.
Samples were then analyzed by using a nano-LC (Ultimate, LC Packing) and
ESI-Q-Tof MS/MS (Q-Tof Ultima API, Micromass). Mass spectrometry data
were analyzed with the MASCOT program (Matrix Science Limited.).
Cell Fusion Assay
PILRa and RFP (TurboRFP, Evrogen) were cotransfected to PILR-ligand neg-
ative CHO cells. gBDC, gD, gH, gL, and GFP were cotransfected into normal
CHO cells. MouseMHC class I Kb was transfected as a control. Two days after
transfection, GFP- or RFP-positive cells were purified by flow cytometry. Fif-
teen thousand CHO cells transfected with HSV-1 glycoproteins and PILRa
were cocultured for 8 hr in 384-well tissue culture plates (Greiner). Cells
were analyzed by fluorescence microscopy (Zeiss), and photographs were
taken with a D50 digital camera (Nikon). Images were processed by Canvas
software (ACD Systems).
Quantative Analysis of PILRa Transcript in Human Tissues
Total RNAs from human various tissues were purchased from Clontech. Total
RNA of human PBMC was isolated by using a RNeasy mini kit (QIAGEN). The
first-strand cDNA was synthesized with random hexamers by using Super-
Script III reverse transcriptase (Invitrogen). Primers used for amplification of
human b-actin and human PILRa were as follows: b-actin, sense primer (50-
GTG ATG GTG GGA ATG GGT CAG-30), anti-sense primer (50-TTT GAT GTC
ACG CAC GAT TTC C-30 ); PILRa, sense (50-AAG GTC AGC AGC GGA CTA
AA-30), anti-sense (50-CAG TCT TGA GAG GGC TGT CC-30). Quantitative
real-time PCR was accomplished with SYBR Green PCRMaster Mix reagents
(Applied Biosystems) and 7900HT First Real-Time PCR System (Applied
Biosystems).
Immunohistochemical Analysis
Formalin-fixed paraffin-embedded tissues were sectioned by standard proto-
cols. Immunohistochemistry was performed using routine methods. Briefly,
4-mm-thick tissue sections were deparaffinized in xylene and dehydrated
with ethanol. The sections were rehydrated with phosphate buffered saline
containing 0.01% Tween-20 (PBST) and incubated with 0.3% hydrogen
peroxidase to quench endogenous peroxidase activity. The sections were
incubated with anti-PILRa or anti-keratin mAbs overnight at 4C, and after
washing with PBST, they were incubated with the Envision Dual Link solution
(Dako, Glostrup, Denmark) for 30 min at room temperature. The reaction prod-
ucts were visualized with diaminobenzidine (Dako), and the nuclei were coun-
terstained with hematoxylin for 90 s. Finally, the slides were mounted with the
Entellan Neu reagent (Merck, Whitehouse Station, NJ) and coverslips for
subsequent analysis.
SUPPLEMENTAL DATA
Supplemental Data include six figures, Supplemental Experimental Proce-
dures, and Supplemental References and can be found with this article online
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